Compare Enzymatica AB with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
SEK 500 Million (Micro Cap)
NA (Loss Making)
NA
0.00%
-0.26
-41.79%
4.03
Revenue and Profits:
Net Sales:
18 Million
(Quarterly Results - Dec 2025)
Net Profit:
-11 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
31.23%
0%
31.23%
6 Months
5.93%
0%
5.93%
1 Year
-46.35%
0%
-46.35%
2 Years
-11.79%
0%
-11.79%
3 Years
-11.21%
0%
-11.21%
4 Years
-58.39%
0%
-58.39%
5 Years
-71.53%
0%
-71.53%
Enzymatica AB for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-13.49%
EBIT Growth (5y)
-214.88%
EBIT to Interest (avg)
-30.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.41
Sales to Capital Employed (avg)
0.38
Tax Ratio
0.15%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.61
EV to EBIT
-8.89
EV to EBITDA
-8.89
EV to Capital Employed
4.76
EV to Sales
9.46
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-53.50%
ROE (Latest)
-36.86%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ
Dec'25
Sep'25
Change(%)
Net Sales
18.30
15.00
22.00%
Operating Profit (PBDIT) excl Other Income
-10.80
-8.30
-30.12%
Interest
0.80
0.10
700.00%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-11.00
-8.40
-30.95%
Operating Profit Margin (Excl OI)
-588.50%
-553.10%
-3.54%
USD in Million.
Net Sales
QoQ Growth in quarter ended Dec 2025 is 22.00% vs 80.72% in Sep 2025
Consolidated Net Profit
QoQ Growth in quarter ended Dec 2025 is -30.95% vs 42.07% in Sep 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
53.90
45.60
18.20%
Operating Profit (PBDIT) excl Other Income
-52.20
-46.90
-11.30%
Interest
1.20
1.70
-29.41%
Exceptional Items
0.00
0.00
Consolidate Net Profit
-51.90
-53.20
2.44%
Operating Profit Margin (Excl OI)
-968.60%
-1,157.70%
18.91%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 18.20% vs -10.41% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 2.44% vs -7.04% in Dec 2024
About Enzymatica AB 
Enzymatica AB
Pharmaceuticals & Biotechnology
Enzymatica publ AB is a Sweden-based company engaged in biotechnology. It researches, develops and registers enzyme-based health and wellbeing products. The Company uses a patented enzyme, Penzyme, a cold-adapted trypsin from deep sea cod. The enzyme is active at about 37 Celsius degree and decomposes disease-related proteins, counteracting viral and bacterial infections and supporting healing processes. The Company conducts clinical studies of ColdZyme Munspray, a cold medicine. It operates such subsidiaries, as Enzymatica Care AB, Zymetech ehf, among others. Main shareholders of Enzymatica AB are Humea AB, Medi AB, and Nordic Consulting Group AB, among others. In November 2013, the Company established another subsidiary in the United States, Enzymatica North America Inc., responsible for future production and sale of veterinary products in the United States and Canada.
Company Coordinates 
Company Details
Ideon Science Park, Scheelevagen 19 , LUND None : 223 70
Registrar Details






